Physician profile
Nancy Hu
NPI 1609212141
$19,310.77
in general payments reported to CMS, 2019-2025
28 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $103 · 2021: $2,416 · 2022: $533 · 2023: $521 · 2024: $182 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14,411.87 | 2019-2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $2,261.63 | 2019-2023 | Ocrevus |
| Abbvie INC. | $679.89 | 2021-2025 | |
| Allergan, INC. | $353.49 | 2019-2022 | |
| Tg Therapeutics, INC. | $282.68 | 2025 | |
| Celgene Corporation | $171.53 | 2023-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $168.25 | 2019-2023 | Lyvispah |
| Sanofi-Aventis U.S. LLC | $129.75 | 2019 | |
| Genzyme Corporation | $112.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $103.56 | 2019-2022 | |
| Amgen INC. | $87.29 | 2019-2025 | Uplizna |
| Mdd US Operations, LLC | $85.07 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $60.73 | 2019-2023 | Nuplazid |
| Emd Serono, INC. | $52.06 | 2023 | |
| Abbott Laboratories | $43.02 | 2023 | Infinity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $36.26 | 2019-2025 | Vyepti |
| Ani Pharmaceuticals, INC. | $34.02 | 2025 | Purified Cortrophin Gel |
| Corium, LLC | $27.25 | 2023 | Adlarity |
| Kyowa Kirin, INC. | $26.39 | 2021 | |
| Ucb, INC. | $25.39 | 2025 | Briviact |
| Merz Pharmaceuticals, LLC | $22.95 | 2024 | Xeomin |
| Adamas Pharmaceuticals, INC. | $22.85 | 2021 | |
| Neurocrine Biosciences, INC. | $21.57 | 2021 | |
| Vertical Pharmaceuticals, LLC | $19.85 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.79 | 2020 | |
| Avion Pharmaceuticals | $17.75 | 2022 | |
| Lilly USA, LLC | $17.72 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.